Loading...
•
Sep 30, 2024
Aclaris Therapeutics Q3 2024 Earnings Report
Aclaris Therapeutics reported its Q3 2024 financial results, marking the dosing of the first patient in the Phase 2a trial of ATI-2138 for moderate to severe atopic dermatitis.
Key Takeaways
Aclaris Therapeutics reported a decrease in revenue for the third quarter of 2024, primarily driven by lower milestone payments compared to the previous year. The company highlighted the dosing of the first patient in the Phase 2a trial of ATI-2138 for atopic dermatitis and anticipates top-line data in the first half of 2025.
First patient dosed in the Phase 2a trial of ATI-2138 for atopic dermatitis.
Aclaris is progressing a second-generation ITK selective inhibitor to development candidate selection for autoimmune indications.
Aclaris is seeking a global development and commercialization partner for lepzacitinib (excluding Greater China).
Aclaris plans to support investigator-initiated trials of zunsemetinib for pancreatic and metastatic breast cancer.
Aclaris Therapeutics
Aclaris Therapeutics
Aclaris Therapeutics Revenue by Segment
Revenue by Segment
Contract research Revenue
CapyFin.comLicensing Revenue
CapyFin.com Forward Guidance
Aclaris anticipates that its cash, cash equivalents and marketable securities as of September 30, 2024 will be sufficient to fund its operations into 2028, without giving effect to any potential business development transactions, financing activities or the outcome of its strategic review.
Revenue & Expenses
Visualization of income flow from segment revenue to net income